GCPGC

Drug Profile

GCPGC

Alternative Names: MG1107; Neulapeg

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Green Cross
  • Developer Green Cross; Mogam Biotechnology Research Institute
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 28 Jul 2016 Launched for Neutropenia (Chemotherapy-induced) in South Korea before July 2016 (SC) (Green Cross pipeline, July 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 02 May 2014 Registered for Neutropenia in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top